Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome

Jingqing Hu

Status: Unknown

Conditions: Coronary Heart Disease

Study type: Observational

Funder types: Other

Identifiers

NCT02967718

2014CB542903

Details and patient eligibility

About

Coronary heart disease is still the major cause of death in China. Chinese medicine plays more and more important role in CHD prevention and treatment. Phlegm and blood stasis are its major pathological basis. Based on that, the investigator aims to evaluate the evolutionary process of CHD phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method so as to guide the clinical treatment of CHD.

Full description

Coronary heart disease (CHD) is a major cause of myocardial infarct (MI) and death induced by atherosclerosis or coronary artery spasm. Despite improvements in interventional and pharmacological therapy for acute MI, the mortality early after AMI remains high. Nowadays, as our life quality develops and dietary structure changes, the morbidity of hyperlipidemia dramatically increased. Based on the Chinese medicine, hyperlipidemia belongs to phlegm and it's the basis of atherosclerosis, blood-stasis is the pathological basis of ischemia. Therefore, the investigator proposes that phlegm and blood-stasis syndrome is the main differentiation on CHD. Based on that, the investigator prospectively and retrospectively explores the evolutionary process of CHD phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method.It will provide evidence and guidance to the future clinical treatment using Chinese medicine.

Enrollment: 13,000 estimated patients

Sex: All

Ages: 35 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy or metabolism syndrome people
• Clinical diagnosis of CHD stable stage or acute coronary disease or CHD heart failure

Exclusion criteria

• Any inflammation, fever, trauma, burn or operation within 1 week
• Obstructive pulmonary disease
• Cerebral vascular disease
• Severe renal or hepatic dysfunction
• Malignant neoplasms
• Hematopoietic system disease
• Sever mental disease

Trial design

13,000 participants in 6 patient groups

Control group

Description:

the healthy patients

Metabolic syndrome group

Description:

Include patients who are accordance with diagnostic criteria of metabolic syndrome

CHD stable stage group

Description:

Include patients who are accordance with diagnostic criteria of asymptomatic angina, stable angina or stable (more than 1 month) acute coronary syndrome

Acute coronary syndrome group

Description:

Include patients who are accordance with diagnostic criteria of unstable angina or non-ST-segment elevated myocardial infarction

PCI or CABG group

Description:

Include the patients who will undergo percutaneous coronary intervention of coronary artery bypass grafting

CHD heart failure group

Description:

Include the patients who suffered heart failure cause by CHD